000070260 001__ 70260
000070260 005__ 20210212121619.0
000070260 0247_ $$2doi$$a10.1093/ckj/sfx149
000070260 0248_ $$2sideral$$a105352
000070260 037__ $$aART-2018-105352
000070260 041__ $$aeng
000070260 100__ $$aKramer, A.
000070260 245__ $$aThe European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: A summary
000070260 260__ $$c2018
000070260 5060_ $$aAccess copy available to the general public$$fUnrestricted
000070260 5203_ $$aBackground: This article summarizes the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry’s 2015 Annual Report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2015 within 36 countries. Methods: In 2016 and 2017, the ERA-EDTA Registry received data on patients who were undergoing RRT for ESRD in 2015, from 52 national or regional renal registries. Thirty-two registries provided individual patient-level data and 20 provided aggregated-level data. The incidence, prevalence and survival probabilities of these patients were determined. Results: In 2015, 81 373 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 119 per million population (pmp). The incidence ranged by 10-fold, from 24 pmp in Ukraine to 232 pmp in the Czech Republic. Of the patients commencing RRT, almost two-thirds were men, over half were aged 65 years and a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 85% of the patients, peritoneal dialysis for 11% and a kidney transplant for 4%. By Day 91 of commencing RRT, 82% of patients were receiving haemodialysis, 13% peritoneal dialysis and 5% had a kidney transplant. On 31 December 2015, 546 783 individuals were receiving RRT for ESRD, corresponding to an unadjusted prevalence of 801 pmp. This ranged throughout Europe by more than 10-fold, from 178 pmp in Ukraine to 1824 pmp in Portugal. In 2015, 21 056 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 31 pmp. This varied from 2 pmp in Ukraine to 94 pmp in the Spanish region of Cantabria. For patients commencing RRT during 2006–10, the 5-year unadjusted patient survival probabilities on all RRT modalities combined was 50.0% (95% confidence interval 49.9–50.1).
000070260 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000070260 590__ $$a2.975$$b2018
000070260 591__ $$aUROLOGY & NEPHROLOGY$$b19 / 80 = 0.237$$c2018$$dQ1$$eT1
000070260 592__ $$a1.092$$b2018
000070260 593__ $$aTransplantation$$c2018$$dQ1
000070260 593__ $$aNephrology$$c2018$$dQ1
000070260 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000070260 700__ $$aPippias, M.
000070260 700__ $$aNoordzij, M.
000070260 700__ $$aStel, V.S.
000070260 700__ $$aAfentakis, N.
000070260 700__ $$aAmbühl, P.M.
000070260 700__ $$aAndrusev, A.M.
000070260 700__ $$aFuster, E.A.
000070260 700__ $$0(orcid)0000-0003-1858-4481$$aArribas Monzón, F.E.$$uUniversidad de Zaragoza
000070260 700__ $$aAsberg, A.
000070260 700__ $$aBarbullushi, M.
000070260 700__ $$aBonthuis, M.
000070260 700__ $$aCaskey, F.J.
000070260 700__ $$aDe la Nuez, P.C.
000070260 700__ $$aCernevskis, H.
000070260 700__ $$aDes Grottes, J.-M.
000070260 700__ $$aGarneata, L.
000070260 700__ $$aGolan, E.
000070260 700__ $$aHemmelder, M.H.
000070260 700__ $$aIoannou, K.
000070260 700__ $$aJarraya, F.
000070260 700__ $$aKolesnyk, M.
000070260 700__ $$aKomissarov, K.
000070260 700__ $$aLassalle, M.
000070260 700__ $$aMacario, F.
000070260 700__ $$aMahillo-Duran, B.
000070260 700__ $$aMartín De Francisco, A.L.
000070260 700__ $$aPalsson, R.
000070260 700__ $$aPechter, Ü.
000070260 700__ $$aResic, H.
000070260 700__ $$aRutkowski, B.
000070260 700__ $$aDe Pablos, C.S.
000070260 700__ $$aSeyahi, N.
000070260 700__ $$aOgrizovic, S.S.
000070260 700__ $$aSlon Roblero, M.F.
000070260 700__ $$aSpustova, V.
000070260 700__ $$aStojceva-Taneva, O.
000070260 700__ $$aTraynor, J.
000070260 700__ $$aMassy, Z.A.
000070260 700__ $$aJager, K.J.
000070260 7102_ $$11008$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Medic.Prevent.Salud Públ.
000070260 773__ $$g11, 1 (2018), 108-122$$pClin. kidney j.$$tClinical kidney journal$$x2048-8505
000070260 8564_ $$s1381965$$uhttps://zaguan.unizar.es/record/70260/files/texto_completo.pdf$$yVersión publicada
000070260 8564_ $$s113478$$uhttps://zaguan.unizar.es/record/70260/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000070260 909CO $$ooai:zaguan.unizar.es:70260$$particulos$$pdriver
000070260 951__ $$a2021-02-12-12:05:55
000070260 980__ $$aARTICLE